Aquinox completes US$14.5 million financing

Guest Contributor
June 18, 2007

Vancouver-based Aquinox Pharmaceuticals Inc has completed a US$14.5-million series ‘A' financing to further develop targeted small molecules therapeutics based on its proprietary SH2-containing inosital phosphatase biochemical enzyme. The enzyme regulates the PI3K pathway for regulating cell growth and survival and immune cell regulation. Aquinox is a spin-off from the Univ of British Columbia and BC Cancer Agency and founded on the research of its four founding scientists — Drs Raymond Anderson, Gerald Krystal, Alice Mui and Christopher Ong. The lead investor is Ventures West Capital Ltd and includes Johnson & Johnson Development Corp, Baker Brothers Corp and BC Advantage Funds.

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.